{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:51:50Z","timestamp":1782172310949,"version":"3.54.5"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.seizure.2019.05.016","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T12:04:34Z","timestamp":1558440274000},"page":"166-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures \u2013 An open-label trial"],"prefix":"10.1016","volume":"71","author":[{"given":"Jose A.","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-1632","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Le Pichon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed T.","family":"Abdelmoity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Dilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dedeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Byrnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2019.05.016_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5698\/1535-7511-12.4s.22","article-title":"AED treatment through different ages: as our brains change, should our drug choices also?","volume":"12","author":"French","year":"2012","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2019.05.016_bib0010","series-title":"Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders, Committee for Medicinal Products for Human Use, London, UK","author":"EMA","year":"2010"},{"key":"10.1016\/j.seizure.2019.05.016_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1586\/14737175.7.2.179","article-title":"Antiepileptic drug treatment in children","volume":"7","author":"Hadjiloizou","year":"2007","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.seizure.2019.05.016_bib0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2019.05.016_bib0025","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.05.016_bib0030","article-title":"Effects of lacosamide and eslicarbazepine acetate metabolites on voltage-gated sodium channel expressed in a neuroblastoma cell line","author":"Ghisdal","year":"2014","journal-title":"Society for Neuroscience 2014 \u2013 44th Annual Meeting"},{"key":"10.1016\/j.seizure.2019.05.016_bib0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.05.016_bib0040","series-title":"(Lacosamide) \u2013 EMA summary of product characteristics","author":"UCB Pharma, SA. Vimpat\u00ae","year":"2018"},{"key":"10.1016\/j.seizure.2019.05.016_bib0045","series-title":"(Lacosamide tablets, injection, oral solution) \u2013 US prescribing information","author":"UCB Inc. Vimpat\u00ae","year":"2019"},{"key":"10.1016\/j.seizure.2019.05.016_bib0050","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.05.016_bib0055","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.05.016_bib0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.05.016_bib0065","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.yebeh.2011.02.005","article-title":"Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy","volume":"20","author":"Gavatha","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.05.016_bib0070","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pediatrneurol.2010.12.003","article-title":"Experience with lacosamide in a series of children with drug-resistant focal epilepsy","volume":"44","author":"Guilhoto","year":"2011","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: a prospective, open-label, observational, multicenter study in Spain","volume":"12","author":"Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R D"},{"key":"10.1016\/j.seizure.2019.05.016_bib0080","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0883073812436741","article-title":"Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study","volume":"27","author":"Rastogi","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","article-title":"Preliminary efficacy and safety of lacosamide in children with refractory epilepsy","volume":"16","author":"Heyman","year":"2012","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: comparison of efficacy and safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.05.016_bib0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.braindev.2013.07.003","article-title":"Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy","volume":"36","author":"Kim","year":"2014","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2019.05.016_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0883073812462887","article-title":"Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy","volume":"29","author":"Yorns","year":"2014","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pediatrneurol.2014.07.004","article-title":"Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy","volume":"51","author":"Pasha","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0115","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1684\/epd.2015.0782","article-title":"Efficacy and safety of lacosamide as an adjunctive therapy for refractory focal epilepsy in paediatric patients: a retrospective single-centre study","volume":"17","author":"Toupin","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2019.05.016_bib0120","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0883073816630084","article-title":"Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy","volume":"31","author":"Miskin","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0125","first-page":"S287","article-title":"Efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal seizures: a randomized, double-blind, placebo-controlled trial","volume":"82","author":"Farkas","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0130","article-title":"Efficacy and tolerability of adjunctive lacosamide in children and adolescents with uncontrolled focal seizures: a randomized, double-blind, placebo-controlled trial","author":"Farkas","year":"2017","journal-title":"American Epilepsy Society 2017 \u2013 71st Annual Meeting"},{"key":"10.1016\/j.seizure.2019.05.016_bib0135","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jcph.1340","article-title":"Population pharmacokinetics of adjunctive lacosamide in pediatric patients with epilepsy","volume":"59","author":"Winkler","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.seizure.2019.05.016_bib0140","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1023\/B:JOPA.0000013000.59346.9a","article-title":"Optimization of individual and population designs using Splus","volume":"30","author":"Retout","year":"2003","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.seizure.2019.05.016_bib0145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.05.016_bib0150","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.05.016_bib0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.seizure.2018.01.014","article-title":"Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: a systematic review","volume":"56","author":"Ortiz de la Rosa","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.05.016_bib0160","article-title":"Long-term tolerability of adjunctive lacosamide in pediatric patients aged 4 to <16 years with focal seizures: an interim pooled analysis of data from open-label trials","author":"Yuen","year":"2017","journal-title":"American Epilepsy Society 2017 \u2013 71st Annual Meeting"},{"key":"10.1016\/j.seizure.2019.05.016_bib0165","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ane.12414","article-title":"Lacosamide cardiac safety: clinical trials in patients with partial-onset seizures","volume":"132","author":"Rudd","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2019.05.016_bib0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yebeh.2016.02.041","article-title":"A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures","volume":"58","author":"Steinhoff","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.05.016_bib0175","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.05.016_bib0180","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.P5.260","article-title":"Tolerability and efficacy of adjunctive lacosamide in children and adolescents with focal seizures in context of presence or absence of sodium-channel blocking AEDs: post-hoc analysis of a randomized, double-blind, placebo-controlled trial","volume":"90","author":"Scheffer","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.05.016_bib0185","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2019.05.016_bib0190","first-page":"1","article-title":"Long-term treatment of 107 patients with lacosamide - experience of the Epilepsy Centre Kork (Germany)","volume":"12","author":"Kurth","year":"2012","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2019.05.016_bib0195","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.05.016_bib0200","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eplepsyres.2011.09.010","article-title":"Initial post marketing experience with lacosamide in adult patients with epilepsy","volume":"98","author":"Harden","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.05.016_bib0205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0404.2012.01704.x","article-title":"Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre","volume":"127","author":"Kamel","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2019.05.016_bib0210","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.yebeh.2011.07.035","article-title":"Adjunctive lacosamide in clinical practice: sodium blockade with a difference?","volume":"22","author":"Stephen","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.05.016_bib0215","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.seizure.2012.05.005","article-title":"Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK)","volume":"21","author":"Flores","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.05.016_bib0220","first-page":"1","article-title":"Effect of lacosamide polytherapy with other sodium channel blockers \u2013 a retrospective study","volume":"12","author":"H\u00f6fler","year":"2012","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.seizure.2019.05.016_bib0225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yebeh.2016.02.007","article-title":"Lacosamide tolerability in adult patients with partial-onset seizures: impact of planned reduction and mechanism of action of concomitant antiepileptic drugs","volume":"57","author":"Foldvary-Schaefer","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.05.016_bib0230","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.eplepsyres.2013.05.002","article-title":"Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation","volume":"106","author":"Novy","year":"2013","journal-title":"Epilepsy Res"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118306344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131118306344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:54:48Z","timestamp":1761011688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131118306344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":46,"alternative-id":["S1059131118306344"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.05.016","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures \u2013 An open-label trial","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}